STAT3 and non-small cell lung carcinoma: Therefore, our results indicated that apatinib might exert its inhibitory effects on NSCLC by targeting VEGFR2/STAT3/PD-L1 signaling in both NSCLC cells and tumor derived macrophages and partially restoring theactivation of T cells.